Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger

0349341 - BTÚ 2011 RIV NL eng J - Článek v odborném periodiku
Ralph, S.J. - Rodriguez-Enriquez, S. - Neužil, Jiří - Moreno-Sanchez, R.
Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger.
Molecular Aspects of Medicine. Roč. 31, č. 1 (2010), s. 29-59. ISSN 0098-2997. E-ISSN 1872-9452
Výzkumný záměr: CEZ:AV0Z50520701
Klíčová slova: Mitocans * reactive oxygen species * anti-cancer drugs
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 10.552, rok: 2010

Mitochondria are emerging as idealized targets for anti-cancer drugs. Although they are inherent to all cells, drugs are being developed that selectively target the mitochondria of malignant cells without adversely affecting normal cells. Such anti-cancer drugs destabilizing mitochondria are referred to as mitocans, classified into several groups according to their mode of action and the location or nature of their specific targets. Many mitocans selectively interfere with the functions of cancer cell mitochondria, causing major disruptions often associated with overloads in ROS production leading to the induction of apoptosis. A common theme emerging is that mitochondrially mediated ROS activation as an apoptosis trigger offers a powerful basis for cancer therapy. Continued research is likely to identify increasing numbers of novel agents that should prove highly effective against a variety of cancers, circumventing tumor resistance to the other more established approaches
Trvalý link: http://hdl.handle.net/11104/0189607